NASDAQ:ABOS Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis $2.56 -0.01 (-0.43%) As of 09:38 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Acumen Pharmaceuticals Stock (NASDAQ:ABOS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acumen Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.60▼$2.6050-Day Range$2.11▼$3.1952-Week Range$1.22▼$3.60Volume722 shsAverage Volume563,258 shsMarket Capitalization$185.06 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer’s disease. The company’s research is centered on amyloid-beta oligomers, toxic protein assemblies that Acumen believes play a key role in the development and progression of neurodegenerative disease. Acumen’s lead product candidate is sabirnetug, formerly known as ACU193, an investigational monoclonal antibody designed to selectively target amyloid-beta oligomers while avoiding much of the amyloid plaque targeted by some other Alzheimer’s therapies. The candidate is being evaluated in clinical studies for its potential to slow or modify disease progression in people with early Alzheimer’s disease. Founded in 1996 and headquartered in Charlottesville, Virginia, Acumen conducts its research and clinical development activities primarily in the United States and through international clinical-trial networks. The company does not currently market an approved commercial product, and its development programs remain subject to clinical, regulatory and other risks.AI Generated. May Contain Errors. Read More Acumen Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreABOS MarketRank™: Acumen Pharmaceuticals scored higher than 59% of companies evaluated by MarketBeat, and ranked 416th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingAcumen Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAcumen Pharmaceuticals has a consensus price target of $7.00, representing about 173.5% upside from its current price of $2.56.Amount of Analyst CoverageAcumen Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Acumen Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.60) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acumen Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acumen Pharmaceuticals is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcumen Pharmaceuticals has a P/B Ratio of 2.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Acumen Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.87% of the float of Acumen Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcumen Pharmaceuticals has a short interest ratio ("days to cover") of 8.24.Change versus previous monthShort interest in Acumen Pharmaceuticals has recently decreased by 1.92%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcumen Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcumen Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentAcumen Pharmaceuticals has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Acumen Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ABOS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows2 people have added Acumen Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acumen Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of Acumen Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Acumen Pharmaceuticals' insider trading history. Receive ABOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABOS Stock News HeadlinesAcumen Pharmaceuticals (NASDAQ:ABOS) Earns Buy Rating from BTIG ResearchSeptember 18 at 1:36 AM | americanbankingnews.comCitigroup Forecasts Strong Price Appreciation for Acumen Pharmaceuticals (NASDAQ:ABOS) StockSeptember 17 at 1:43 AM | americanbankingnews.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.September 18 at 1:00 AM | Paradigm Press (Ad)Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day TranscriptSeptember 16 at 8:00 PM | seekingalpha.comAcumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026September 10, 2026 | globenewswire.comAcumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeptember 10, 2026 | seekingalpha.comAcumen Pharmaceuticals to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | globenewswire.comAcumen Pharmaceuticals Earnings Call: Science vs. RunwayAugust 23, 2026 | tipranks.comSee More Headlines ABOS Stock Analysis - Frequently Asked Questions How have ABOS shares performed this year? Acumen Pharmaceuticals' stock was trading at $2.11 on January 1st, 2026. Since then, ABOS stock has increased by 21.3% and is now trading at $2.5590. How were Acumen Pharmaceuticals' earnings last quarter? Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its earnings results on Wednesday, August, 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. Read the conference call transcript. When did Acumen Pharmaceuticals IPO? Acumen Pharmaceuticals (ABOS) raised $150 million in an initial public offering on Tuesday, June 29th 2021. The company issued 9,999,999 shares at a price of $14.00-$16.00 per share. Who are Acumen Pharmaceuticals' major shareholders? Acumen Pharmaceuticals' top institutional shareholders include BlackRock Inc. (3.45%), ADAR1 Capital Management LLC (2.92%), Bank of America Corp DE (0.38%) and Bank of New York Mellon Corp (0.17%). Insiders that own company stock include Daniel Joseph Oconnell, Matt Zuga, Eric Siemers, Russell Barton, Derek M Meisner, James J Doherty, Nathan B Fountain and Derrell Porter. View institutional ownership trends. How do I buy shares of Acumen Pharmaceuticals? Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acumen Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acumen Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Tesla (TSLA), Meta Platforms (META), NVIDIA (NVDA) and Netflix (NFLX). Company Calendar Last Earnings8/12/2026Today9/18/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ABOS's financial health is in the Green zone, according to TradeSmith. ABOS has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABOS CIK1576885 Webwww.acumenpharm.com Phone434-297-1000FaxN/AEmployees61Year Founded1996Price Target and Rating Average Price Target for Acumen Pharmaceuticals$7.00 High Price Target$8.00 Low Price Target$5.00 Potential Upside/Downside+173.1%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$121.33 million Net MarginsN/A Pretax MarginN/A Return on Equity-136.27% Return on Assets-81.64% Debt Debt-to-Equity Ratio0.21 Current Ratio2.47 Quick Ratio2.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book2.21Miscellaneous Outstanding Shares72,317,000Free Float64,941,000Market Cap$185.35 million OptionableOptionable Beta0.37 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ABOS) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | SponsoredThis Gold Explorer Is Approaching Its Biggest Milestone YetA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acumen Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acumen Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
